LOGIN  |  REGISTER
C4 Therapeutics

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 28, 2024 | Last Trade: US$5.85 0.17 2.99

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:

Jefferies Global Healthcare Conference 
Date: Wednesday, June 5, 2024, at 2:00 p.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat

Goldman Sachs 45th Annual Global Healthcare Conference 
Date: Wednesday, June 12, 2024, at 11:20 a.m. ET
Location: Loews Miami Beach Hotel in Miami, FL
Format: Fireside Chat

Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days. 

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page